Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 7,631 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Peripheral Vascular Diseases, Intermittent Claudication
Interventions: Propionyl-L-Carnitine, PLC; Drug
Lead sponsor: Sigma-Tau Research, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: Jacksonville, Florida • Pensacola, Florida • LaGrange, Illinois + 6 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 192
States / cities: Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more

Conditions: Breast Cancer
Interventions: nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery; Biological · Drug · Other + 1 more
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
Interventions: Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration, Quality-of-Life Assessment; Other · Behavioral
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 526
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more

Conditions: Helicobacter Pylori Infection
Interventions: Vonoprazan, Amoxicillin, Clarithromycin, Lansoprazole; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,046 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 106
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 84 more

Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Interventions: avutometinib (VS-6766) and adagrasib; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 5 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 111 more

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Arcadia, California • Beverly Hills, California • Escondido, California + 43 more

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Diabetic Foot Ulcer
Interventions: COMS One device, Sham device; Device
Lead sponsor: Piomic Medical; Industry
Eligibility: 22 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Castro Valley, California + 23 more

Conditions: Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
Interventions: InterStim Micro; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Jacksonville, Florida • Tampa, Florida • Jeffersonville, Indiana + 13 more

Conditions: Bipolar I Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more

Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
Interventions: Panitumumab, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride; Biological · Other · Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 18
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Music Therapy
Interventions: Music Therapy; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypertension
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 119
States / cities: Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more

Conditions: Tumor, Breast Cancer
Interventions: NKTR-102; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • Rancho Mirage, California • Stockton, California + 5 more

Conditions: Asthma
Interventions: Fluticasone 44 mcg, Fluticasone 220 mcg; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 18
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 11 more

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 288
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more

Conditions: Solid Tumor, Adult
Interventions: DF9001, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more

Conditions: Breast Cancer
Interventions: letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 172
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more

Conditions: Peripheral Artery Disease
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 13,885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 290
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 14 more

Conditions: Fibromyalgia
Interventions: TRIPP VR Meditation, Sham VR; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

InterStim Micro Post Market Clinical Follow-up Study (ELITE)

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Study of Music Therapy in Pain Rehabilitation Programs

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Study of DF9001 in Patients With Advanced Solid Tumors

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Study Of Virtual Reality Vs Sham VR On Fibromyalgia